Further studies revealed that RHOJ promotes EMT-mediated invasion and metastasis of GC via the IL-6/STAT3 signaling, and showed a possibility that RHOJ is a selective prognostic biomarker and a promising therapeutic target for GC patients. The gene discussed is IL6; the disease is gastric cancer.